



ASX ANNOUNCEMENT

Release of Shares from Escrow

MELBOURNE, Australia (18 November 2021): Lumos Diagnostics (ASX: LDX) advises that, in accordance with ASX Listing Rule 3.10A and as stated in the Prospectus dated 7 June 2021 and the Pre-Quotation Disclosure dated 1 July 2021, 9,836,309 fully paid ordinary shares will be released from escrow on 26 November 2021.

These shares are already quoted on ASX.

This announcement has been authorised for release to the market by the Company Secretary.

###

About Lumos Diagnostics

Lumos Diagnostics specialises in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information about Lumos Diagnostics and the CovidX SARS-CoV-2 rapid antigen test, visit lumosdiagnostics.com.

Media Contacts (U.S. and Global):

Jennifer Christiansen – Lumos Diagnostics
jennifer.christiansen@lumosdiagnostics.com
+1 920 784 3153

Media Contact (Australia):

Haley Chartres – H^CK
haley@hck.digital
+61 423 139 163

Investor Contact:

Matthijs Smith
ir@lumosdiagnostics.com
+61 411 137 080
+61 3 9087 1598

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
+61 3 9087 1598